Our findings provide validated novel altered proteins -LGALS3BP, Layilin, MICB, CD36, DDIT3, TOPORS and XIAP- non-previously associated to AD that should be further explored in subsequent studies to determine their usefulness as blood or CSF biomarkers and should be the focus of functional experiments to determine their role in AD to potentially identify new targets of AD intervention. This evidence concerns the gene LAYN and Alzheimer disease.